To date, a number of potential, selective, central dopamine (DA) autoreceptor agonists have been presented (Figure 1). We were the first group to report on such a profile for racemic 3-PPP (Hjorth et al., 1980). That report was based upon data from our in vivo screening method which consists of a biochemical (DA synthesis rate) and a behavioral part (locomotor activity) assay. This gives the valuable information as to the pre-/postsynaptic relationship of the test compound. Interesting compounds are, of course, further tested in other biochemical and functional models to ascertain their pharmacological profile in greater detail. In these two basic models, racemic 3-PPP appears to be selective for DA autoreceptors since it decreases the DA synthesis rate without inducing any signs of locomotor activity in reserpinized rats. As the “3-PPP story” has developed, with resolution and extensive testing of the 3-PPP enantiomers, it now seems clear that R(+)-3-PPP is a classical DA receptor agonist with both pre-and postsynaptic agonist effects. S(−)-3-PPP is a partial agonist with an intrinsic efficacity of about 60% (striatum) in the biochemical (DA synthesis rate) γ-butyrolactone (GBL) model (acute DA autoreceptor agonist model). Table I gives the corresponding data for apomorphine and some other autoreceptor agonists.
KeywordsDopamine Schizophrenia Piperidine Apomorphine Lisuride
Unable to display preview. Download preview PDF.
- Allinger, N. L; Yuh, Y. (1980). Quantum Chemistry Program Exchange, program 13, 395.Google Scholar
- Andén, N.-E.; Golembiowska-Nikitin, K.; Nilsson, H.; Ros, E.; Thornström, U. (1983). Effects of Two Azepine derivatives (BH-T 920 and B-HT 933) on Pre- and Postsynaptic Dopamine Receptors in the Brain. Acta Pharm. Suec. Suppl. 1, 154–164.Google Scholar
- Brücke, T.; Danielczyk, W.; Simànyi, M.; Sofie, E.; Riederer, P. (1986). Terguride: Partial Dopamine Agonist in the Treatment of Parkinson’s Disease. Advances in Neurology, 45, 573–576. Edited by M. D. Yahr and K. J. Bergmann. Raven Press, new York, 1986.Google Scholar
- Corsini, G. U.; Horowski, R.; Rainer, E.; Del Sompo, L. (1984). Treatment of Parkinson’s disease with a dopamine partial agonist. Clin. Neuropharmacol., 7 (Suppl. 1), 950–951.Google Scholar
- Hjorth, S.; Carlsson, A.; Lindberg, P.; Sanchez, D.; Wikström, H.; Arvidsson, L.-E.; Hacksell, U.; Nilsson, J. L. G.; Svensson, U. (1980). A New Centrally Acting DA Receptor Agonist with Selectivity for Autoreceptors. Proceedings of the 18th ACNP Meeting, San Juan, Puerto Rico, December 12–14, 1979. Proceedings: Psychopharmacol. Bull., 16, 85–90.Google Scholar
- Kehr, W.; Wachtel, H.; Schneider, H. H. (1983). Dopaminergic and Antidopaminergic Properties of Ergolines Structurally related to Lisuride. Acta Pharm. Suec. Suppl. 2, 98–110.Google Scholar
- Svensson, K.; Hjorth, S.; Clark, D.; Carlsson, A.; Wikström, H.; Andersson, B.; Sanchez, D.; Johansson, A. M.; Arvidsson, L-E.; Hacksen, U.; Nilsson, J. L G. (1986). (+)-UH232 and (+)-UH242: Novel Stereoselective Dopamine Receptor Antagonists with Preferential Action on Autoreceptors. J. Neural Transm., 65, 1–27.CrossRefPubMedGoogle Scholar